Build A Bear Workshop Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Build A Bear Workshop Inc trades at $32.95 (market cap $412.61M), while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 166.7× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| BBW | REGN | |
|---|---|---|
Market Cap | $412.61M | $68.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $812.27 |
52-Week Low | $29.84 | $542.52 |
Enterprise Value | $512.05M | $62.74B |
Dividend Yield | 2.8% | 0.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Trailing returns across standard periods
Latest headlines on both assets
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →